Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oral LY3493269 in Healthy Participants
NCT05794243Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LY3493269 in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity at Day 3, Area Under the Concentration Versus Time Curve During One Dosing Interval at Day 3 and 1 more. Started Mar 2023; status: terminated.
02
Drugs
LY3493269
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05794243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794243.